69 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
27838170	2	An evaluation of central penetration from a peripherally administered oxytocin receptor selective antagonist in nonhuman primates.	Emory University
11992786	42	Identification of potent and selective oxytocin antagonists. Part 1: indole and benzofuran derivatives.	Glaxosmithkline
11392542	25	Structure-activity relationship investigations of a potent and selective benzodiazepine oxytocin antagonist.	Glaxosmithkline
27297999	37	Systematic N-methylation of oxytocin: Impact on pharmacology and intramolecular hydrogen bonding network.	Pfizer
26741855	65	Flexible analogues of WAY-267,464: Synthesis and pharmacology at the human oxytocin and vasopressin 1a receptors.	The University Of Sydney
25654260	49	Discovery of highly selective brain-penetrant vasopressin 1a antagonists for the potential treatment of autism via a chemogenomic and scaffold hopping approach.	F. Hoffmann-La Roche
25642985	45	Selective nonpeptidic fluorescent ligands for oxytocin receptor: design, synthesis, and application to time-resolved FRET binding assay.	University Of Strasburg
24874785	333	New, potent, and selective peptidic oxytocin receptor agonists.	Ferring Research Institute
25408829	10	Pyrazolsulfonamide agonists of oxytocin receptor.	Dart Neuroscience
16250654	41	2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists. 2. Synthesis, chirality, and pharmacokinetics.	Glaxosmithkline
23978650	2	Investigation of an F-18 oxytocin receptor selective ligand via PET imaging.	Emory University
23270988	4	Carbon-11 N-methyl alkylation of L-368,899 and in vivo PET imaging investigations for neural oxytocin receptors.	Yerkes National Primate Research Center
21700453	56	Optimisation of pharmacokinetic properties to afford an orally bioavailable and selective V1A receptor antagonist.	Msd
21146408	53	The characterization of a novel V1b antagonist lead series.	Glaxosmithkline
20674355	58	Pyrrolo[1,2-a]pyrazine and pyrazolo[1,5-a]pyrazine: novel, potent, and selective series of Vasopressin 1b receptor antagonists.	Glaxosmithkline
19081251	38	Discovery and optimisation of a potent and selective tertiary sulfonamide oxytocin antagonist.	Glaxosmithkline
22984902	59	Selective fluorescent nonpeptidic antagonists for vasopressin V2 GPCR: application to ligand screening and oligomerization assays.	University Of Strasburg
22239250	59	Pyridyl-2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists: synthesis, pharmacokinetics, and in vivo potency.	Glaxosmithkline
22425346	28	Synthesis and evaluation of C-11, F-18 and I-125 small molecule radioligands for detecting oxytocin receptors.	Emory University
20104850	48	Subtlety of the structure-affinity and structure-efficacy relationships around a nonpeptide oxytocin receptor agonist.	University Of Strasburg
19800231	92	Tetrahydroquinoline sulfonamides as vasopressin 1b receptor antagonists.	Schering-Plough Research Institute
19095447	28	Discovery and optimization of highly ligand-efficient oxytocin receptor antagonists using structure-based drug design.	Glaxosmithkline
18032036	17	The discovery of GSK221149A: a potent and selective oxytocin antagonist.	Glaxosmithkline
17850055	18	Toward efficient drug screening by homogeneous assays based on the development of new fluorescent vasopressin and oxytocin receptor ligands.	Institute Genomics Functional (Igf)
17300166	88	Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasopressin at positions 4 and 8.	University Of Montpellier
16302826	129	Discovery and development of a new class of potent, selective, orally active oxytocin receptor antagonists.	Serono Pharmaceutical Research Institute
15084136	96	Design of potent and selective agonists for the human vasopressin V1b receptor based on modifications of [deamino-cys1]arginine vasopressin at position 4.	Medical College Of Ohio
13678399	54	Peptide science: exploring the use of chemical principles and interdisciplinary collaboration for understanding life processes.	University Of Arizona
12036367	46	Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V(1)(a) receptors.	University Of Montpellier
7507528	23	Enhanced selectivity of oxytocin antagonists containing sarcosine in position 7.	Max-Planck-Institut F£R Biophysik
1331448	101	Development of a novel class of cyclic hexapeptide oxytocin antagonists based on a natural product.	Merck Research Laboratories
10201826	24	Synthesis of oxytocin antagonists containing conformationally constrained amino acids in position 2.	Albert Szent-Gy£Rgyi Medical University
21688787	295	New, potent, selective, and short-acting peptidic V1a receptor agonists.	Ferring Research Institute
21605973	69	Potent and selective oxindole-based vasopressin 1b receptor antagonists with improved pharmacokinetic properties.	Abbott Laboratories
21601454	26	Identification and optimisation of novel sulfonamide, selective vasopressin V1B receptor antagonists.	Msd
21428295	43	Design, synthesis, and pharmacological characterization of fluorescent peptides for imaging human V1b vasopressin or oxytocin receptors.	University Of Montpellier
21353540	55	Synthesis and SAR studies of novel 2-(4-oxo-2-aryl-quinazolin-3(4H)-yl)acetamide vasopressin V1b receptor antagonists.	Msd
21117646	25	Modulating oxytocin activity and plasma stability by disulfide bond engineering.	The University Of Queensland
20550119	96	Oral oxytocin antagonists.	Drugmoldesign
20719508	26	Identification and optimization of novel 2-(4-oxo-2-aryl-quinazolin-3(4H)-yl)acetamide vasopressin V3 (V1b) receptor antagonists.	Ligand Pharmaceuticals
20189387	46	Identification of amide bioisosteres of triazole oxytocin antagonists.	Pfizer
20172721	21	Identification of a urea bioisostere of a triazole oxytocin antagonist.	Pfizer
19963374	68	Triazole oxytocin antagonists: Identification of an aryloxyazetidine replacement for a biaryl substituent.	Pfizer
19376698	16	Aryloxypyrazines as highly selective antagonists of Oxytocin.	Pfizer
19053774	56	New benzylureas as a novel series of potent, nonpeptidic vasopressin V2 receptor agonists.	Vantia
18778939	23	Triazole oxytocin antagonists: identification of aryl ether replacements for a biaryl substituent.	Pfizer
18639455	43	Design and optimization of potent, selective antagonists of Oxytocin.	Pfizer
17855087	19	Identification and synthesis of major metabolites of Vasopressin V2-receptor agonist WAY-151932, and antagonist, Lixivaptan.	Wyeth Research
17316912	63	Synthesis and biological activity of oxytocin analogues containing conformationally-restricted residues in position 7.	University Of Patras
16821776	13	2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists. 3. Synthesis, pharmacokinetics, and in vivo potency.	Cardiovascular And Urogenital Centre Of Excellence For Drug Discovery
15357997	22	Non-peptide oxytocin agonists.	Ferring Research
11992787	37	Identification of potent and selective oxytocin antagonists. Part 2: further investigation of benzofuran derivatives.	Glaxosmithkline
11520211	7	Design, synthesis and pharmacological characterization of a potent radioiodinated and photoactivatable peptidic oxytocin antagonist.	University Of Montpellier
11392541	2	Identification of a potent and selective oxytocin antagonist, from screening a fully encoded differential release combinatorial chemical library.	Glaxosmithkline
10522694	4	The synthesis of a new class of oxytocin antagonists.	Ferring Research Institute
10340620	30	Nonpeptide oxytocin antagonists: analogs of L-371,257 with improved potency.	Merck Research Laboratories
10197974	22	Fluorescent pseudo-peptide linear vasopressin antagonists: design, synthesis, and applications.	University Of Montpellier
9873680	21	Nonpeptide oxytocin antagonists: potent, orally bioavailable analogs of L-371,257 containing a 1-R-(pyridyl)ethyl ether terminus.	Merck Research Laboratories
9703459	5	Peptidomimetic growth hormone secretagogues. Design considerations and therapeutic potential.	Merck Research Laboratories
9622556	63	Development of orally active oxytocin antagonists: studies on 1-(1-[4-[1-(2-methyl-1-oxidopyridin-3-ylmethyl)piperidin-4-yloxy]-2- methoxybenzoyl]piperidin-4-yl)-1,4-dihydrobenz[d][1,3]oxazin-2-one (L-372,662) and related pyridines.	Merck Research Laboratories
8258821	491	Nanomolar-affinity, non-peptide oxytocin receptor antagonists.	Merck Research Laboratories
7473590	37	1-(1-[4-[(N-acetyl-4-piperidinyl)oxy]-2-methoxybenzoyl]piperidin-4- yl)-4H-3,1-benzoxazin-2(1H)-one (L-371,257): a new, orally bioavailable, non-peptide oxytocin antagonist.	Merck Research Laboratories
28438540	207	Potent and selective oxytocin receptor agonists without disulfide bridges.	Takeda Pharmaceutical
25035921	44	Pyrazolopyrimidines Establish MurC as a Vulnerable Target in Pseudomonas aeruginosa and Escherichia coli.	Astrazeneca India